See more : Devsisters corporation (194480.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InDex Pharmaceuticals Holding AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- InBody Co.,Ltd (041830.KQ) Income Statement Analysis – Financial Results
- Unisync Corp. (USYNF) Income Statement Analysis – Financial Results
- Entire Technology Co., Ltd. (6775.TWO) Income Statement Analysis – Financial Results
- India Cements Capital Limited (INDCEMCAP.BO) Income Statement Analysis – Financial Results
- Commercial Metals Company (CMC) Income Statement Analysis – Financial Results
InDex Pharmaceuticals Holding AB (publ) (INDEX.ST)
About InDex Pharmaceuticals Holding AB (publ)
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 97.51M | 1.15M | 440.00K | 35.00K | 88.00K | 128.00K | 113.00K | 176.00K | 376.00K | 45.16M |
| Cost of Revenue | 193.21M | 10.29M | 14.38M | 16.02M | 3.90M | 560.00K | 9.00M | 6.30M | 1.42M | 4.99M |
| Gross Profit | -95.71M | -9.14M | -13.94M | -15.99M | -3.82M | -432.00K | -8.89M | -6.13M | -1.05M | 40.17M |
| Gross Profit Ratio | -98.16% | -797.64% | -3,168.86% | -45,674.29% | -4,335.23% | -337.50% | -7,862.83% | -3,480.11% | -278.19% | 88.94% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 87.74M | 30.99M | 70.19M | 78.98M | 54.83M | 24.31M | 19.51M | 40.92M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 187.84M | 150.05M | 87.74M | 30.99M | 70.19M | 78.98M | 54.83M | 24.31M | 19.51M | 40.92M |
| Other Expenses | 0.00 | 139.68M | 13.07M | 10.37M | 13.71M | 8.95M | 9.61M | 9.11M | 8.92M | 11.43M |
| Operating Expenses | 200.72M | 139.68M | 100.81M | 41.36M | 83.90M | 87.93M | 64.43M | 33.42M | 28.43M | 52.35M |
| Cost & Expenses | 193.21M | 149.97M | 115.19M | 57.38M | 87.80M | 88.49M | 73.43M | 39.73M | 29.85M | 57.35M |
| Interest Income | 12.33M | 3.01M | 133.00K | 46.00K | 61.00K | 0.00 | 0.00 | 1.00K | 6.00K | 1.79M |
| Interest Expense | 227.00K | 120.00K | 133.00K | 113.00K | 61.00K | 6.00K | 40.00K | 1.70M | 413.00K | 1.00K |
| Depreciation & Amortization | 1.22M | 4.08M | 1.25M | 1.24M | 939.00K | 11.00K | 11.00K | 67.00K | 95.00K | 111.00K |
| EBITDA | -93.82M | -150.05M | -114.38M | -56.11M | -86.77M | -82.30M | -72.71M | -39.50M | -29.37M | -10.28M |
| EBITDA Ratio | -96.91% | -8,651.57% | -23,104.09% | -160,322.86% | -98,605.68% | -64,295.31% | -64,343.36% | -22,445.45% | -7,811.97% | -22.77% |
| Operating Income | -95.71M | -103.23M | -102.91M | -57.35M | -87.71M | -82.37M | -73.32M | -39.55M | -29.47M | -12.19M |
| Operating Income Ratio | -98.16% | -9,007.59% | -23,388.64% | -163,854.29% | -99,672.73% | -64,347.66% | -64,880.53% | -22,471.02% | -7,838.83% | -26.98% |
| Total Other Income/Expenses | 443.00K | 49.64M | 12.15M | -69.00K | -61.00K | 50.00K | 556.00K | -1.73M | -407.00K | -2.68M |
| Income Before Tax | -95.27M | -100.33M | -103.04M | -57.42M | -87.77M | -82.32M | -72.76M | -41.28M | -29.88M | -10.40M |
| Income Before Tax Ratio | -97.70% | -8,755.06% | -23,418.86% | -164,051.43% | -99,742.05% | -64,308.59% | -64,388.50% | -23,451.70% | -7,947.07% | -23.02% |
| Income Tax Expense | 0.00 | -2.89M | 133.00K | 113.00K | 61.00K | 6.06M | 596.00K | -22.00K | 6.00K | 4.48M |
| Net Income | -95.27M | -97.44M | -103.18M | -57.53M | -87.83M | -82.32M | -72.76M | -41.28M | -29.88M | -14.87M |
| Net Income Ratio | -97.70% | -8,502.53% | -23,449.09% | -164,374.29% | -99,811.36% | -64,308.59% | -64,388.50% | -23,451.70% | -7,947.07% | -32.93% |
| EPS | -0.18 | -0.18 | -0.21 | -0.24 | -0.45 | -0.18 | -0.44 | -0.41 | -0.37 | -0.09 |
| EPS Diluted | -0.18 | -0.18 | -0.21 | -0.24 | -0.45 | -0.18 | -0.44 | -0.41 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 532.69M | 532.69M | 483.37M | 236.75M | 197.00M | 452.92M | 166.74M | 101.63M | 80.18M | 159.54M |
| Weighted Avg Shares Out (Dil) | 532.69M | 532.69M | 483.37M | 236.75M | 197.00M | 452.92M | 166.74M | 101.63M | 80.18M | 159.54M |
Source: https://incomestatements.info
Category: Stock Reports